会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Substituted quinuclidines as substance P antagonists
    • 取代的奎宁化合物作为P物质拮抗剂
    • US5837711A
    • 1998-11-17
    • US428240
    • 1995-04-28
    • Fumitaka ItoToshihide KokuraMasami NakaneKunio SatakeHiroaki Wakabayashi
    • Fumitaka ItoToshihide KokuraMasami NakaneKunio SatakeHiroaki Wakabayashi
    • C07D453/02A61K31/44
    • C07D453/02
    • Certain novel substituted quinuclidine compounds having the ability to antagonize substance P and having the following formula: ##STR1## wherein Ar.sup.1 and Ar.sup.2 are each, independently, thienyl, phenyl, fluorophenyl, chlorophenyl or bromophenyl; X is --CONR.sup.3 R.sup.4, --CO.sub.2 R.sup.3, --CH.sub.2 OR.sup.3, --CH.sub.2 NR.sup.3 R.sup.4 or --CONR.sup.3 OR.sup.4 ; R.sup.1, R.sup.3 and R.sup.4 are each, independently, hydrogen or alkyl having 1 to 4 carbon atoms; R.sup.2 is alkyl having 1 to 4 carbon atoms; Y is alkylsulfonyl having 1 to 4 carbon atoms, N-alkyl-N-alkanoylamino (which may be substituted by halogen in the alkanoyl moiety) having 1 to 4 carbon atoms in the alkyl and the alkanoyl moieties, N-alkyl-N-alkylsulfonylamino (which may be substituted by halogen in the alkylsulfonyl moiety) having 1 to 4 carbon atoms in the alkyl and the alkyl sulfonyl moieties, alkenyl having 2 to 4 carbon atoms, alkynyl having 2 to 4 carbon atoms, halosubstituted alkyl having 1 to 4 carbon atoms, alkylamino having 1 to 4 carbon atoms, alkanoylamino (which may be substituted by halogen) having 1 to 4 carbon atoms or alkylsulfonylamino (which may be substituted by halogen) having 1 to 4 carbon atoms. These compounds are useful in the treatment gastrointestinal or central nervous system disorders and the alleviation of inflammatory diseases, asthma, pain and migraine in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.
    • PCT No.PCT / US93 / 09169 Sec。 371日期:1995年4月28日 102(e)日期1995年4月28日PCT 1993年9月30日PCT公布。 出版物WO94 / 10170 日期:1994年5月11日具有拮抗物质P并具有下式的新颖取代的奎宁环化合物:其中Ar 1和Ar 2各自独立地为噻吩基,苯基,氟苯基,氯苯基或溴苯基; X是-CONR 3 R 4,-CO 2 R 3,-CH 2 OR 3,-CH 2 NR 3 R 4或-CONR 3 OR 4; R 1,R 3和R 4各自独立地为氢或具有1至4个碳原子的烷基; R2是具有1至4个碳原子的烷基; Y是具有1至4个碳原子的烷基磺酰基,在烷基和烷酰基部分中具有1至4个碳原子的N-烷基-N-烷酰基氨基(其可被烷酰基部分中被卤素取代)为N-烷基-N-烷基磺酰基氨基 (其可以被烷基磺酰基部分中的卤素取代)在烷基和烷基磺酰基部分中具有1至4个碳原子,具有2至4个碳原子的烯基,具有2至4个碳原子的炔基,具有1至4个碳原子的卤代烷基 原子,具有1至4个碳原子的烷基氨基,具有1至4个碳原子的烷酰基氨基(其可以被卤素取代)或具有1至4个碳原子的烷基磺酰基氨基(可被卤素取代)。 这些化合物可用于治疗哺乳动物的胃肠道或中枢神经系统疾病和减轻炎性疾病,哮喘,疼痛和偏头痛,并用作用于治疗这些病症的药物组合物中的活性成分。
    • 7. 发明授权
    • Quinuclidine derivatives as substance P antagonists
    • 奎宁环衍生物作为物质P拮抗剂
    • US5569662A
    • 1996-10-29
    • US313289
    • 1994-10-03
    • Kunio SatakeHiroaki WakabayashiMasami Nakane
    • Kunio SatakeHiroaki WakabayashiMasami Nakane
    • C07D453/02A61K31/445
    • C07D453/02
    • Compounds useful in the treatment of inflammatory disorders, central nervous system disorders and other disorders of formula (I) and the pharmaceutically-acceptable salts thereof, wherein X.sup.1 is alkoxy or halosubstituted alkoxy; X.sup.2 is hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halosubstitued alkyl, halosubstituted alkoxy, alkylamino, dialkylamino, alkylsulfonylamino (which may be substituted), N-alkyl-N-alkylsulfonylamino (which may be substituted), alkanoylamino (which may be substituted) or N-alkyl-N-alkanoylamino (which may be substituted); Ar.sup.1 and Ar.sup.2 are each, independently, thienyl, phenyl, fluorophenyl, chlorophenyl or bromophenyl; A is Y--(CH.sub.2).sub.m --CH(R.sup.2)--(CH.sub.2).sub.n --NR.sup.1 --; R.sup.1 is hydrogen, alkyl, benzyl or --(CH.sub.2).sub.p --Y; R.sup.2 is hydrogen, alkyl (which may be substituted), benzyl, 4-hydroxybenzyl, 3-indolylmethyl or --(CH.sub.2).sub.p --Y; Y is --CN, --CH.sub.2 Z or --COZ; Z is hydroxy, amino, alkoxy, alkylamino or dialkylamino; m, n and p are each, independently, 0, 1, 2 or 3; and R.sup.1 and R.sup.2 may be connected to form a ring.
    • PCT No.PCT / US93 / 01810 Sec。 371日期:1994年10月3日 102(e)日期1994年10月3日PCT 1993年3月5日PCT公布。 WO93 / 19064 PCT公开号 日期1993年9月30日可用于治疗炎症性疾病,中枢神经系统疾病和式(I)的其它病症及其药学上可接受的盐的化合物,其中X1是烷氧基或卤代取代的烷氧基; X 2是氢,卤素,烷基,烯基,炔基,烷氧基,烷硫基,烷基亚磺酰基,烷基磺酰基,卤素取代的烷基,卤代烷氧基,烷基氨基,二烷基氨基,烷基磺酰基氨基(其可被取代的),N-烷基-N-烷基磺酰基氨基 ),烷酰基氨基(其可以被取代)或N-烷基-N-烷酰基氨基(其可以被取代); Ar1和Ar2各自独立地为噻吩基,苯基,氟苯基,氯苯基或溴苯基; A是Y-(CH 2)m -CH(R 2) - (CH 2)n -NR 1; R1是氢,烷基,苄基或 - (CH2)p-Y; R 2是氢,烷基(其可以被取代),苄基,4-羟基苄基,3-吲哚基甲基或 - (CH 2)p-Y; Y是-CN,-CH2Z或-COZ; Z是羟基,氨基,烷氧基,烷基氨基或二烷基氨基; m,n和p各自独立地为0,1,2或3; 并且R1和R2可以连接形成环。
    • 8. 发明授权
    • Vehicle seat
    • 车座
    • US09193286B2
    • 2015-11-24
    • US13486307
    • 2012-06-01
    • Sakae OkuyamaMasami Nakane
    • Sakae OkuyamaMasami Nakane
    • A47C31/02B60N2/58A47C7/18
    • B60N2/5825A47C7/18A47C31/02B60N2/5816B60N2/5841
    • A vehicle seat including: a seat component including, a cushion material forming an outer shape of the vehicle seat, a plurality of groove parts formed to the cushion material and intersecting each other, a corner part formed by intersection of the plurality of groove parts, and a skin material covering the cushion material, wherein the skin material covers the cushion material while a portion of the skin material is engaged inside the plurality of groove parts in a pulled state, wherein the cushion material includes a protruding portion protruding from an external portion of the corner part, and wherein the protruding portion covers the external portion of the corner part and shrinks toward the external portion of the corner part by a pressing force of the skin material engaged inside the plurality of groove parts in the pulled state.
    • 一种车辆座椅,包括:座椅部件,包括形成所述车辆座椅的外部形状的缓冲材料,形成在所述缓冲材料上并相互交叉的多个槽部,通过所述多个槽部的交叉形成的角部, 以及覆盖所述衬垫材料的表皮材料,其中所述表皮材料覆盖所述衬垫材料,同时所述表皮材料的一部分在拉伸状态下接合在所述多个凹槽部分内,其中所述衬垫材料包括从外部突出的突出部分 并且其中所述突出部分覆盖所述拐角部分的外部,并且在所述拉伸状态下通过所述多个凹槽部分内的所述表皮材料的压力而朝所述角部的外部收缩。
    • 9. 发明授权
    • 7-thiabicycloheptane substituted diamide and its congener prostaglandin
analogs
    • 7-硫杂双环庚烷取代的二酰胺及其同类前列腺素类似物
    • US4735962A
    • 1988-04-05
    • US916083
    • 1986-10-06
    • Masami Nakane
    • Masami Nakane
    • C07D495/08C07D409/06C07D333/78
    • C07D495/08
    • 7-Thiabicycloheptane substituted diamide and congener prostaglandin analogs are provided having the structural formula ##STR1## wherein m is 1 to 4; A is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; n is 1 to 5; R is CO.sub.2 H, CO.sub.2 alkyl, CO.sub.2 alkali metal, CO.sub.2 polyhydroxyamine salt, --CH.sub.2 OH, ##STR2## wherein R.sup.3 and R.sup.4 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl, at least one of R.sup.3 and R.sup.4 being other than hydroxy and lower alkoxy; p is 1 to 4; Z is ##STR3## q is 1 to 12; R.sup.1 is H or lower alkyl; and R.sup.3 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, arylalkyloxy, amino, alkylamino arylamino, arylalkylamino, ##STR4## (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl.The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.
    • 提供7-噻二环庚烷取代的二酰胺和同系物前列腺素类似物,其结构式为:其中m为1至4; A是-CH = CH-或-CH 2 -CH 2 - ; n为1至5; R为CO 2 H,CO 2烷基,CO 2碱金属,CO 2多羟基胺盐,-CH 2 OH,其中R 3和R 4相同或不同,为H,低级烷基,羟基,低级烷氧基或芳基,R 3和R 4中的至少一个为其它 羟基和低级烷氧基; p为1〜4; Z是 + TR q是1到12; R1是H或低级烷基; 并且R 3是H,低级烷基,低级烯基,低级炔基,芳基,芳基烷基,低级烷氧基,芳氧基,芳基烷氧基,氨基,烷基氨基芳基氨基,芳烷基氨基,(其中n'是0,1或2) 烷基氨基烷基,芳基氨基烷基,芳基烷基氨基烷基,烷氧基烷基,芳氧基烷基或芳基烷氧基烷基。 这些化合物是可用于例如治疗血栓形成疾病的心血管药。
    • 10. 发明授权
    • 7-oxabicycloheptane substituted aminoalkyl amide prostaglandin analogs
    • 7-氧杂双环庚烷取代的氨基烷基酰胺前列腺素类似物
    • US4656185A
    • 1987-04-07
    • US804729
    • 1985-12-05
    • Steven E. HallMasami Nakane
    • Steven E. HallMasami Nakane
    • A61K31/557A61P7/02A61P9/00A61P9/08A61P9/10A61P11/08C07D493/08C07D405/14
    • C07D493/08
    • 7-Oxabicycloheptane substituted diacid diamide prostaglandin analogs are provided having the structural formula ##STR1## wherein m is 0 to 4; A is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; n is 1 to 5; R is CO.sub.2 H, CO.sub.2 alkyl, CO.sub.2 alkali metal, CO.sub.2 polyhydroxyamine salt, --CH.sub.2 OH ##STR2## wherein R.sup.4 and R.sup.5 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl, at least one of R.sup.4 and R.sup.5 being other than hydroxy and lower alkoxy; p is 1 to 4; R.sup.1 is H or lower alkyl; q is 1 to 12; R.sup.2 and R.sup.3 are the same or different and are H, lower alkly, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aralkyloxy, cycloalkyl or cycloalkylalkyl.The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.
    • 提供7-氧杂双环庚烷取代的二酸二酰胺前列腺素类似物,其结构式为:其中m为0至4; A是-CH = CH-或-CH 2 -CH 2 - ; n为1至5; R为CO 2 H,CO 2烷基,CO 2碱金属,CO 2多羟基胺盐,-CH 2 OH其中R 4和R 5相同或不同,为H,低级烷基,羟基,低级烷氧基或芳基,R 4和R 5中的至少一个为 羟基和低级烷氧基; p为1〜4; R1是H或低级烷基; q为1〜12; R2和R3相同或不同,为H,低级烷基,低级烯基,低级炔基,芳基,芳烷基,低级烷氧基,芳烷氧基,环烷基或环烷基烷基。 这些化合物是可用于例如治疗血栓形成疾病的心血管药。